STOCK TITAN

Notifications

Limited Time Offer! Get Platinum at the Gold price until January 31, 2026!

Sign up now and unlock all premium features at an incredible discount.

Read more on the Pricing page

Sera Prognostics, Inc. SEC Filings

SERA NASDAQ

Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.

Reading a biotech filing can feel like decoding lab results in another language, especially when Sera Prognostics’ disclosures span clinical-trial endpoints, cash-burn tables and biomarker patents. If you have ever wondered how to track Sera Prognostics insider trading Form 4 transactions before pivotal data releases or needed to locate R&D spend buried deep in the notes, you know the challenge.

Stock Titan solves that problem. Our platform delivers AI-powered summaries that turn a 300-page 10-K into a two-minute brief, flagging exactly where the company discusses pre-term birth biomarkers, partnership milestones and patent litigation risks. Real-time alerts surface every filing type the moment it hits EDGAR, including:

  • Sera Prognostics quarterly earnings report 10-Q filing with segment growth and burn-rate trends
  • Sera Prognostics annual report 10-K simplified for long-term obligations and IP strategy
  • Sera Prognostics proxy statement executive compensation to benchmark leadership incentives
  • Sera Prognostics 8-K material events explained for clinical-trial results or financing updates
  • Sera Prognostics Form 4 insider transactions real-time so you never miss an executive stock move

Whether you’re analysing cash runway, comparing quarter-over-quarter biomarker adoption, or simply understanding Sera Prognostics SEC documents with AI, Stock Titan streamlines your workflow. Use the Sera Prognostics earnings report filing analysis to assess revenue from diagnostic sales, or dive into Sera Prognostics executive stock transactions Form 4 for sentiment signals. Complex biotech disclosures are now clear, timely and actionable—no scientific background required.

Filing
Rhea-AI Summary

Sera Prognostics, Inc. (SERA) Form 144 notice reports a proposed sale of 1,458 common shares by an insider through Morgan Stanley Smith Barney LLC on 09/02/2025 on NASDAQ. The filing shows an aggregate market value of $4,709.34 for the proposed sale and lists 37,094,109 shares outstanding. The shares to be sold were acquired as restricted stock units on 05/15/2024. The filer also reported three recent sales during the past three months by the same person totaling 18,313 shares for gross proceeds of $55,139.26 on 06/10/2025, 08/08/2025, and 08/29/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

Sera Prognostics insider sale reported. Paul Kearney, Chief Data Officer, filed a Form 4 disclosing a sale of 10,542 shares of Class A common stock on 08/29/2025 at a reported price of $3.49 per share. After the transaction Mr. Kearney beneficially owned 178,398 shares, held directly. The filing states the trade was executed under a Rule 10b5-1 trading plan adopted May 21, 2025, indicating the sale was preplanned rather than a discretionary transaction. The Form 4 was signed by an attorney-in-fact on behalf of the reporting person on 09/02/2025.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Sera Prognostics (SERA) Form 144 notice reports a proposed sale of 10,542 common shares with an aggregate market value of $32,469.36 through Morgan Stanley Smith Barney on NASDAQ, with an approximate sale date of 08/29/2025.

The shares were acquired as restricted stock units from the issuer on 02/06/2024. The filer also reported recent disposals in the past three months: 6,460 shares sold on 08/08/2025 for $16,408.40 and 1,311 shares sold on 06/10/2025 for $1,940.28. The filer certifies no undisclosed material adverse information and includes standard Notice and signature statements.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Harrison Robert Gardner, Chief Information Officer of Sera Prognostics, Inc. (SERA), reported a sale of 6,000 shares of Class A common stock on 08/20/2025 under a pre-existing Rule 10b5-1 trading plan adopted May 21, 2025. The shares were sold at a weighted average price of $2.22, with executed prices ranging from $2.17 to $2.25. After the sales, the reporting person beneficially owned 102,577 shares directly. The Form 4 was filed by one reporting person and signed by an attorney-in-fact on the same date.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Filing
Rhea-AI Summary

Form 144 notice for SERA (Sera Prognostics, Inc.) reporting proposed sale of common stock by Robert Gardner Harrison. The filing lists 6,000 shares to be sold through Morgan Stanley Smith Barney LLC with an aggregate market value of $13,500.00 and an approximate sale date of 08/20/2025. The shares were acquired as Restricted Stock Units on 02/06/2024. The issuer's outstanding shares are shown as 37,094,109. The filing also discloses recent sales by the same person: 5,962 shares sold on 08/08/2025 for $15,143.48 and 667 shares sold on 06/10/2025 for $987.16. The notice includes the required representation that the seller is not aware of undisclosed material adverse information about the issuer.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
-
Rhea-AI Summary

RA Capital Management, L.P., RA Capital Healthcare Fund, L.P., Peter Kolchinsky and Rajeev Shah filed an amended Schedule 13G reporting no beneficial ownership of Sera Prognostics, Inc. (SERA) Class A common stock as of June 30, 2025. The filing lists each reporting person’s citizenship and principal business address and states that each holds 0 shares and 0.0% of the class. The filers expressly disclaim status as a group and certify the securities were not acquired to influence control of the issuer. A joint filing agreement is incorporated by reference.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
other
Rhea-AI Summary

Sera Prognostics (SERA) reporting person Zhenya Lindgardt, who serves as Chief Executive Officer and Director, reported a mandated sale to satisfy tax withholding on vested restricted stock units. On 08/08/2025 the reporting person sold 8,571 shares in a block trade at a weighted average price of $2.54; individual trade prices ranged from $2.28 to $2.73. The Form states the sale was required by the issuer's election to use "sell to cover" and was not a discretionary transaction by the reporting person.

Following the sale the reporting person beneficially owned 832,294 shares directly. The Form 4 was executed by an attorney-in-fact and filed with the SEC on 08/11/2025. No derivative transactions were reported in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Insider sale to cover RSU tax withholding. Kearney Paul, Chief Data Officer of Sera Prognostics (SERA), sold 6,460 shares of Class A common stock on 08/08/2025 as a mandated sell-to-cover to satisfy tax withholding associated with RSU vesting. The filing states this was not a discretionary transaction by the reporting person. The block trade produced a weighted-average price of $2.54, with transaction prices ranging from $2.28 to $2.73.

The reporting person continues to directly beneficially own 188,940 shares. The filer notes it will provide a per-price breakdown of the block trade to the SEC or other parties upon request. No derivative transactions were reported in this filing.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
-
Rhea-AI Summary

Benjamin G. Jackson, General Counsel of Sera Prognostics, reported the sale of 6,447 shares of Class A common stock on 08/08/2025 to satisfy tax withholding on vested restricted stock units. The filing states this was a mandatory "sell-to-cover" transaction and not a discretionary sale. The shares were executed as a block trade at a weighted average price of $2.54, with individual trade prices ranging from $2.28 to $2.73.

Following the sale the reporting person beneficially owns 127,751 shares on a direct basis. No derivative securities were reported. The disclosure documents an administrative, tax-related disposition rather than an elective insider sale.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider
Rhea-AI Summary

Robert Gardner, Chief Information Officer and director at Sera Prognostics, sold shares to satisfy tax withholding from restricted stock units. The Form 4 reports a non-discretionary "sell to cover" transaction on 08/08/2025 in which 5,962 Class A common shares were sold as a block at prices ranging from $2.28 to $2.73, with a weighted average price of $2.54. After the sale the reporting person beneficially owns 108,577 shares. The filing states the sale was mandated by the issuer to satisfy tax obligations and that detailed per-price breakdowns for the block trade will be provided on request. No derivative securities were reported.

Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
insider

FAQ

What is the current stock price of Sera Prognostics (SERA)?

The current stock price of Sera Prognostics (SERA) is $3.4 as of November 25, 2025.

What is the market cap of Sera Prognostics (SERA)?

The market cap of Sera Prognostics (SERA) is approximately 130.5M.
Sera Prognostics, Inc.

NASDAQ:SERA

SERA Rankings

SERA Stock Data

130.45M
33.40M
10.8%
64.96%
1.88%
Medical Devices
Services-medical Laboratories
Link
United States
SALT LAKE CITY